Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Preferred Stock Liabilities (2022 - 2025)

Envoy Medical's Preferred Stock Liabilities history spans 3 years, with the latest figure at $130000.0 for Q3 2025.

  • For Q3 2025, Preferred Stock Liabilities changed N/A year-over-year to $130000.0; the TTM value through Sep 2025 reached $130000.0, changed N/A, while the annual FY2022 figure was $429.7 million, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q3 2025 was $130000.0 at Envoy Medical, down from $44.6 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $429.7 million in Q4 2022 and bottomed at $130000.0 in Q3 2025.
  • The 3-year median for Preferred Stock Liabilities is $425.0 million (2022), against an average of $256.5 million.
  • The largest YoY upside for Preferred Stock Liabilities was 89.51% in 2023 against a maximum downside of 89.61% in 2023.
  • A 3-year view of Preferred Stock Liabilities shows it stood at $429.7 million in 2022, then crashed by 89.62% to $44.6 million in 2023, then crashed by 99.71% to $130000.0 in 2025.
  • Per Business Quant, the three most recent readings for COCH's Preferred Stock Liabilities are $130000.0 (Q3 2025), $44.6 million (Q2 2023), and $44.2 million (Q1 2023).